Recommended

Download this feature partnership: Continuous manufacturing: an evolving technology for drug substance manufacturing
New webinar: Defining the right digital strategy for oncology: What do you want to measure?
Join now: Pharmaceutical continuous manufacturing: what’s next for industry?
Register now for our upcoming webinar: Enhancing oral drug delivery: Exploring multiparticulate systems
Download our latest in-depth focus to read articles on single temperature incubation, endotoxin standards and aseptic connections in pharma manufacturing.
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps
Register now: Simplifying complex dosage forms with advanced encapsulation
Join our webinar: Unmasking the unknown: how mass spectrometry delivers accurate identifications

List view / Grid view

Sanofi

 

Sanofi logo
Sanofi logo
news

Journal of Clinical Oncology publishes Phase III results of ZALTRAP® (aflibercept) VELOUR study

8 October 2012 | By

Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that detailed results from the pivotal Phase III VELOUR study evaluating ZALTRAP® (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer were published in the October 2012 edition of the Journal of Clinical Oncology (JCO).

S
S
news

New data from ORIGIN

5 October 2012 | By Sanofi

New data from ORIGIN shows Lantus® use is about 3 times more likely to achieve and sustain target HbA1c vs. standard care over 5 years in the study population...